65 Grove Street
About Lyndra Therapeutics
TRANSFORMING THE WAY WE TAKE MEDICINE FOR A HEALTHIER WORLD
ULTRA-LONG-ACTING ORAL DOSING IS ACHIEVABLE
Our Team has developed the first ultra-long-acting pill that lasts a week or longer and can provide a wide range of medicines in a familiar oral capsule form. Once inside the stomach, the capsule delivers steady amounts of medicine for seven days or more. Our once-weekly product has safely demonstrated gastric residence with predictable pharmacokinetics in humans. There are no other oral products which provide ultra-long-acting therapeutic coverage or a controlled, steady delivery of medicine which can reduce side effects and improve drug efficacy, resulting in measurable health outcomes.
At Lyndra, we ask “What if we stopped trying to change the patient and changed the pill instead?"
17 articles with Lyndra Therapeutics
$13 Million Bill & Melinda Gates Foundation Grant to Fund Development Program to Address Lack of Family Planning Options Globally
Lyndra Therapeutics and Gilead Sciences to Collaborate on Development of Ultra-Long-Acting HIV Therapeutics
Gilead will have exclusive rights to Lyndra’s platform for HIV therapies
Gilead is paying Lyndra $15 million upfront to develop a formulation for HIV that can be taken once a week, as opposed to every day.
6/7/2019Pharma and biotech companies strengthen their executive and leadership teams with new appointments.
Addition to management team strengthens Lyndra’s development capabilities
NIH Grant Fuels Development of Once-Weekly Oral Buprenorphine
Lyndra Therapeutics today announced it has raised $55 million in Series B financing, funds it will use for Phase II clinical trials, expansion of its Phase I pipeline and manufacturing scale-up.
The funds raised will be used to advance the company’s lead product into Phase II clinical trials, expand its Phase I pipeline, and scale-up its manufacturing capacity.
Lyndra Therapeutics today announced a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for intellectual property (IP) related to Lyndra’s ultra-long-acting oral drug delivery system. This indicates that the patent application has cleared internal review and is pending issuance.
Lyndra Therapeutics Reports Positive Results from Pharmacokinetics (PK) Study of its Ultra-long-acting Oral Dosage Form
Study shows viability of taking once-weekly pill
Lyndra Inc. and Global Drug Commercialization Center Announce Joint Venture to Develop Lyndra’s Ultra-Long-Acting Oral Dosage Form for Chinese Market
Announcement comes as Lyndra CEO Amy Schulman’s TEDMED talk is released to the public; Schulman featured as “visionary entrepreneur”
Lyndra Announces Publication of Feasibility Study of Oral Once-Weekly Drug Delivery System for HIV Antiretroviral Therapy in Nature Communications
Lyndra announced the publication of a feasibility study of an oral, once-weekly drug delivery platform for HIV antiretroviral therapy in the peer-reviewed journal Nature Communications.
Lyndra Announces Addition Of Kelly Lindert, M.D., Senior Vice President Clinical Development & Strategy And Jacqueline Schumacher, Vice President Regulatory, As Company Moves Towards Clinical Development
Lyndra Secures Funding From The National Institute Of Allergy And Infectious Diseases For The Development Of Ultra-Long Acting Oral HIV Therapies